Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a
subsidiary of Luye Pharma Group, will orally present the
pre-clinical data of its proprietary CD3+ T-cell engager platform
and CEA/CD3 bispecific antibody at World Bispecific Summit
2021.
The annual World Bispecific Summit aiming to promote the
development of bispecific antibody therapies will take place for
the 12th time this year. It has become a prestigious
platform in the industry for academic exchanges. The upcoming event
will take place online from September 29 to
October 1, 2021 Eastern Standard Time.
Details of the oral presentation by Boan Biotech are as
follows:
Title: Optimization of CD3+ T-cell Engager to
Improve Safety Profile
Session: T-cell Based Approaches for Oncology
Therapeutics
Time: October 1, 2021
Background
CD3+ T-cell engagers are a group of the most promising
bispecific antibodies for the treatment of cancers. But they face
major challenges including the dose-limiting, life threatening
cytokine release syndrome (CRS) toxicity, suboptimal potency, and
the on-target off-tumor toxicity. To overcome those challenges,
Boan Biotech developed an optimized platform for CD3+ bispecific
T-cell engagers with a unique combination of high potency, reduced
cytokine release and tumor-targeting selectivity.
The CEA/ CD3 bispecific antibody BA1202 is the first clinical
candidate developed on the leading bispecific T-cell Engager
platform. The pre-clinical research data of BA1202 showed a high
potency in killing cancer cells, significantly reduced cytokine
release, and superior efficacy.
In addition to BA1202, multiple bispecific antibody candidates
with similar optimized format and the reduced CD3 affinity have
been validated both in vitro and in vivo to have a
similar advantage against different solid tumor targets. Boan
Biotech plans to speed up the effort to take these bispecific
T-cell engagers as investigational drugs to clinical trials, to
address the huge unmet needs in treating patients with late-stage
cancers.
About Boan Biotech
As a subsidiary of Luye Pharma Group, Boan Biotech is a fully
integrated biopharmaceutical company that specializes in
therapeutic antibody development, manufacturing and
commercialization with a focus on oncology, immunology, pain, and
endocrine diseases. Boan Biotech's antibody discovery work is based
on three technology platforms: Human Antibody Transgenic Mouse and
Phage Display Technology Platform, Bispecific T-cell Engager
Technology Platform and ADC Technology Platform. The company has
developed more than 10 innovative antibody product candidates with
international intellectual property protection, and 8 biosimilar
product candidates, one of which – Boyounuo (Bevacizumab Injection)
– has been launched in China.
Boan Biotech has expertise in the full industry chain: antibody
generation, lead optimization, cell line development, process
development, technology transfer, pilot and commercial scale
production. The company is also actively exploring other
cutting-edge technologies. Its cell therapy products use non-viral
vectors for CAR-T for late stage solid tumors. In addition, Boan
Biotech is exploring novel off-the-shelf CAR-T and regulatable
CAR-T, to develop safer, effective and affordable products for
patients. Outside of China, Boan
Biotech also pursues biopharmaceutical products development in the
US and EU markets.
View original
content:https://www.prnewswire.com/news-releases/boan-biotech-to-present-the-pre-clinical-data-of-its-proprietary-cd3-t-cell-engager-platform-and-ceacd3-bispecific-antibody-at-world-bispecific-summit-301385115.html
SOURCE Luye Pharma Group